title: Anti-CD3 enhancement of cellular cytotoxicity in cancer patients treated with interleukin-2.
abstract: Anti-CD3 monoclonal antibody was found to enhance non-MHC restricted cellular cytotoxicity in vitro in the peripheral blood mononuclear cells from normal healthy individuals. This effect was dose dependent (maximal at 0.11 micrograms/ml) and was complete within 30 minutes. Peripheral blood mononuclear cells from 4 out of 8 cancer patients treated with Interleukin-2 were deficient in their ability to respond to anti-CD3 in vitro. In contrast, peripheral blood mononuclear cells from cancer patients who subsequently displayed a tumour response to Interleukin-2, were able to respond to anti-CD3 by enhanced non-MHC restricted cellular cytotoxicity. This study demonstrates the importance of CD3+ lymphocytes in the generation of antitumour activity following in vivo Interleukin-2 administration and the ability of CD3+ve lymphocytes to respond to anti-CD3 in vitro may indicate those patients who would benefit from Interleukin-2 therapy.
authors.affiliation: Department of Surgery, General Hospital, Leicester, England.
authors.forename: S S
authors.initials: SS
authors.lastname: Ubhi
authors.forename: T
authors.initials: T
authors.lastname: Horsburgh
authors.forename: P S
authors.initials: PS
authors.lastname: Veitch
authors.forename: P R
authors.initials: PR
authors.lastname: Bell
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000494:pharmacology; D015703:Antigens, CD / Q000276:immunology*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology*; D017252:CD3 Complex; D002460:Cell Line; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D007376:Interleukin-2; D011948:Receptors, Antigen, T-Cell; D011994:Recombinant Proteins; D005472:Fluorouracil